Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Sep 27, 2024; 16(9): 2769-2773
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2769
Personalized treatment of perihilar cholangiocarcinoma based on tumor genetic and molecular characteristics
He-Nan Tang, Ming-Wei Wang, Xue-Song Liu, Yan Jiao
He-Nan Tang, Department of Outpatient, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Ming-Wei Wang, Ministry of Health Key Laboratory of Radiobiology, School of Public Health of Jilin University, Changchun 130000, Jilin Province, China
Xue-Song Liu, Department of Gastrointestinal Surgery, Changchun Central Hospital, Changchun 130000, Jilin Province, China
Yan Jiao, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Jiao Y designed the overall concept and outline of the manuscript; Tang HN contributed to the discussion and design of the manuscript; Tang HN, Wang MW, and Liu XS contributed to the writing, and editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: The authors have claimed no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Jiao, MD, PhD, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, General surgery center, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Received: March 16, 2024
Revised: June 12, 2024
Accepted: June 21, 2024
Published online: September 27, 2024
Processing time: 185 Days and 21.7 Hours
Core Tip

Core Tip: Genetic and molecular profiling of perihilar cholangiocarcinoma (pCCA) has identified a number of key abnormalities that drive tumor growth and spread. pCCA is still hard to treat, and individualized anticancer treatment is required, which is supposed to be according to the genetic and molecular features. The personalized treatment should be explored to improve outcomes for patients with this challenging disease.